Clinical trials for Gastrointestinal stromal tumor
47 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 1NCT07171203Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal TumorUniversity of California, San Diego · PI: Paul Fanta, MD
- RECRUITINGN/ANCT07405125Safety of Robotic Surgery for GISTs at Special Anatomic SitesThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPhase 3NCT07218926A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib TherapyGlaxoSmithKline
- RECRUITINGPhase 1NCT06655246A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)Kura Oncology, Inc.
- RECRUITINGN/ANCT06926374Prospective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic SurgeryChinese University of Hong Kong · PI: Simon SM Ng, MD
- RECRUITINGN/ANCT07411118RCT of EFTR Versus STER for GIST TreatmentChinese University of Hong Kong · PI: Hon Chi Yip
- RECRUITINGPHASE1, PHASE2NCT06630234A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)Deciphera Pharmaceuticals, LLC · PI: Clinical Team
- RECRUITINGPhase 3NCT06640361A Study of Olverembatinib in SDH-deficient GIST.Ascentage Pharma Group Inc. · PI: Ruihua Xu, M.D., Ph.D.
- ACTIVE NOT RECRUITINGPhase 2NCT06208748SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GISTSarcoma Alliance for Research through Collaboration · PI: Candace Haddox, MD
- ACTIVE NOT RECRUITINGPhase 2NCT06087263Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.M.D. Anderson Cancer Center · PI: Neeta Somaiah
- RECRUITINGNCT06431451The Correlation Between Ripretinib Exposure and the Efficacy and Safety in Patients with Advanced GISTsFirst Affiliated Hospital, Sun Yat-Sen University
- RECRUITINGN/ANCT06507683Evaluate the Efficacy and Safety of Radiotherapy Combined With Ripretinib in the Treatment of Unresectable Advanced GISTFirst Affiliated Hospital of Chongqing Medical University · PI: Jun Zhang
- RECRUITINGPhase 2NCT05493215Imatinib TDM in GISTReema A. Patel · PI: Reema Patel, MD
- RECRUITINGN/ANCT06748690MCB vs EUS-FNA for Preoperative Pathological Evaluation of Gastric SMTPeking University People's Hospital · PI: Liming Zhang, M.D.
- ACTIVE NOT RECRUITINGPhase 3NCT05734105A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With ImatinibDeciphera Pharmaceuticals, LLC · PI: Clinical Team
- RECRUITINGPhase 2NCT05366816ctDNA-Guided Sunitinib And Regorafenib Therapy for GISTUniversity of Miami · PI: Jonathan Trent, MD, PhD
- RECRUITINGPHASE1, PHASE2NCT05957367A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced MalignanciesDeciphera Pharmaceuticals, LLC · PI: Clinical Team
- RECRUITINGPhase 2NCT05905887Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal TumorAsan Medical Center
- RECRUITINGPhase 2NCT05661643The Efficacy and Safety of Temozolomide in SDH-deficient GISTAsan Medical Center
- RECRUITINGNCT05867901Clinical Research of Drug Holiday Based on MRD Detection in GIST Patients at High Risk of RecurrencePeking University People's Hospital · PI: Zhidong Gao, MD
- RECRUITINGNCT05938309A Cohort Study on the Safety of Laparoscopic Resection of 5cm or Larger Gastric Gastrointestinal Stromal TumorsFujian Medical University
- RECRUITINGNCT05804331The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection StudyWestern Sydney Local Health District · PI: Michael Bourke
- RECRUITINGN/ANCT05751733Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GISTXiangya Hospital of Central South University
- RECRUITINGPhase 2NCT053855495 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High RiskAsan Medical Center
- RECRUITINGPhase 1NCT05489237First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal TumorsIDRx Inc. - A GSK Company
- RECRUITINGNCT05461664Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRAXinhua Zhang, MD · PI: Xinhua Zhang, PhD
- RECRUITINGNCT05464875A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal TumorsXinhua Zhang, MD · PI: Xinhua Zhang, PhD
- RECRUITINGNCT05440357Second-line Pharmacotherapy Patterns and Outcomes of Advanced Gastrointestinal Stromal Tumor: A Real-world StudyXinhua Zhang, MD · PI: zhang xinhua, PhD
- ACTIVE NOT RECRUITINGPhase 3NCT05208047(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal TumorsCogent Biosciences, Inc.
- RECRUITINGPhase 2NCT05152472A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard TreatmentsCentre Leon Berard · PI: Mehdi BRAHMI, MD
- RECRUITINGPhase 2NCT05009927Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)Centre Leon Berard · PI: Jean-Yves BLAY, Pr
- RECRUITINGNCT05408897Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRDPeking University People's Hospital · PI: Yingjiang Ye
- ACTIVE NOT RECRUITINGPhase 1NCT05245968A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)Taiho Pharmaceutical Co., Ltd. · PI: Taiho Pharmaceutical Co., Ltd.
- RECRUITINGPhase 2NCT04933669Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal TumorsFirst Affiliated Hospital of Zhejiang University · PI: Jiren Yu
- ACTIVE NOT RECRUITINGNCT04821895Oncogenetic Panel and Integrated Clinical Data Registry Study for Wild Type Gastrointestinal Stromal Tumor PatientsNational Health Research Institutes, Taiwan · PI: Hui-Jen Tsai, M.D.
- ACTIVE NOT RECRUITINGN/ANCT05038254Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse EventsM.D. Anderson Cancer Center · PI: Ryan W Huey, MD
- ACTIVE NOT RECRUITINGPhase 2NCT04595747Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)National Cancer Institute (NCI) · PI: Suzanne George
- ACTIVE NOT RECRUITINGPhase 3NCT03673501A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With ImatinibDeciphera Pharmaceuticals, LLC
- RECRUITINGNCT03602092Observational Registry Data on GIST PatientsNational Health Research Institutes, Taiwan · PI: Tsang-Wu Liu, M.D
- RECRUITINGNCT03716089Comparison of Tumor Efficacy Safety in Laparoscopic Resection of Gastrointestinal Stromal Tumors Between Favorable and Unfavorable SiteFujian Medical University
- ACTIVE NOT RECRUITINGPhase 2NCT03556384Temozolomide (TMZ) in Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)Adam Burgoyne, MD, PhD · PI: Adam Burgoyne, MD, PhD
- RECRUITINGPhase 1NCT03594422A Study of HQP1351 in Patients With GIST or Other Solid TumorsAscentage Pharma Group Inc. · PI: Ruihua Xu, Professor
- ACTIVE NOT RECRUITINGPhase 3NCT02413736Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GISTHeikki Joensuu · PI: Heikki Joensuu
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT01991379MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)Memorial Sloan Kettering Cancer Center · PI: Ping Chi, MD, PhD
- ACTIVE NOT RECRUITINGPhase 4NCT01742299Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the InvestigatorNovartis Pharmaceuticals · PI: Novartis Pharmaceuticals
- ACTIVE NOT RECRUITINGPhase 2NCT00265798Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib MalateNational Cancer Institute (NCI) · PI: Hedy L Kindler
- RECRUITINGNCT01048281Clinical & Pathological Studies of Upper Gastrointestinal CarcinomaStanford University · PI: James M Ford